Clinical features of hypertrophic pachymeningitis in a center survey
- 28 Downloads
Hypertrophic pachymeningitis (HP) is characterized by cranial and/or spinal thickening of the dura mater with or without associated inflammation. Neuroimaging studies reveal dura mater thickening and focal or diffuse contrast enhancement. It is described in association with trauma, infections, tumors, autoimmune/inflammatory diseases, and cerebrospinal fluid hypotension syndrome, with some cases remaining idiopathic.
A retrospective study was conducted with patients’ identification through a key terms search within MRI reports in the period of July 2008 to September 2015. Clinical files, MRI, laboratory, and pathology data were reviewed.
Fifty-three patients were identified and 20 were excluded because they did not meet the inclusion criteria. Of the 33 included, 19 were female, with a mean age at symptoms onset of 51.2 ± 17.6 years. The most common presenting symptoms were headache and cranial nerves palsy, followed by seizures, delirium, lumbar pain, cognitive decline, motor deficit, and language impairment. In 17 patients, a neoplastic etiology was identified; in eight, inflammatory/autoimmune; in six, infectious; and two were classified as idiopathic. Of the eight patients with inflammatory/autoimmune etiology, four had possible IgG4-related disease (IgG4-RD) and the remaining had granulomatosis with polyangiitis, sarcoidosis, rheumatoid arthritis, and Tolosa-Hunt syndrome. Treatment was directed according to the underlying etiology.
In the described series, a female predominance was identified, with symptoms’ onset in the 5th decade. Although headache was the most common symptom, clinical presentation was varied, emphasizing the role of MRI in HP diagnosis. The underlying etiologies were diverse, with only a few cases remaining idiopathic, also reflecting the contribution of the recently described IgG4-RD.
KeywordsHypertrophic pachymeningitis Neurological symptoms Magnetic resonance imaging IgG4-related disease
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
- 3.Mott FW (1909) A case of localized syphilitic pachymeningitis cerebri. Arch Neurol Psychiatr 4:63–69Google Scholar
- 5.Yonekawa T, Murai H, Utsuki S, Matsushita T, Masaki K, Isobe N, Yamasaki R, Yoshida M, Kusunoki S, Sakata K, Fujii K, Kira JI (2014) A nationwide survey of hypertrophic pachymeningitis in Japan. J Neurol Neurosurg Psychiatry 85(7):732–739. https://doi.org/10.1136/jnnp-2013-306410 CrossRefPubMedGoogle Scholar
- 11.Tan HJ, Raymond A, Phadke PP, Rozman Z (2004) Rheumatoid pachymeningitis. Singap Med J 45(7):337–339Google Scholar
- 15.Noel N, Drier A, Wechsler B, et al. (2014) Neurological manifestations of Behçet’s disease. Rev Med Interne 35(2):112–20. https://doi.org/10.1016/j.revmed.2013.10.332
- 16.Yu WL, Bhatia KSS, Wang K (2012) Hypertrophic Pachymeningitis as the first manifestation of systemic lupus erythematosus. Hong Kong J Radiol 15:119–122Google Scholar
- 20.Briani C, Fedrigo M, Manara R, Castellani C, Zambello R, Citton V, Campagnolo M, Torre CD, Lucchetta M, Orvieto E, Rotilio A, Marangoni S, Magi S, Pareyson D, Florio I, Pegoraro E, Thiene G, Battistin L, Adami F, Angelini A (2012) Pachymeningeal involvement in POEMS syndrome: MRI and histopathological study. J Neurol Neurosurg Psychiatry 83(1):33–37. https://doi.org/10.1136/jnnp-2011-300047 CrossRefPubMedGoogle Scholar